← Back to Patent Explorer
US4923857A Expired / Lapsed US ⏱️ 0.0 years remaining

3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds

Assignee: Astellas Pharma Inc
•
Filing: 1989-02-17
•
Granted: 1990-05-08
•
Expires: 2009-02-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to an antimicrobial compound of the formula: ##STR1## in which R 1 is carboxy or protected carboxy, R 2 is hydroxy(lower)alkyl or protected hydroxy(lower)alkyl, R 3 and R 4 are each hydrogen or lower alkyl, and R 5 is saturated 4 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) or saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), wherein said aliphatic heterocyclic group may be substituted by one or more suitable substituent(s) selected from a group consisting of hydroxy, protected hydroxy, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, halogen, lower alkoxy, lower alkyl, lower alkoxy(lower)alkyl, imino, protected imino, lower alkylamino, protected lower alkylamino, mono(or di)-(lower)alkylcarbamoyloxy, lower alkylidene, lower alkanimidoyl and imino-protective group, or pharmaceutically acceptable salts thereof.

Inventors

  • 👤 Masayoshi Murata
  • 👤 Toshiyuki Chiba
  • 👤 Akira Yamada

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 21:23
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/02; C07D487/04; C07D477/00; C07D477/10; C07D477/12; C07D477/14; A; A61; A61P; A61P31/00; A61P31/04

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 141 words
A compound of the formula: ##STR71## in which R 1 is carboxy or protected carboxy, R 2 is hydoxy(lower)alkyl or protected hydroxy(lower)alkyl, R 3 and R 4 are each hydrogen or lower alkyl, and R 5 is saturated 4 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) or saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), wherein said aliphatic heterocyclic group may be substituted by one or more suitable substituent(s) selected from a group consisting of hydroxy, protected hydroxy, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, halogen, lower alkoxy, lower alkyl, lower alkoxy(lower)alkyl, imino, protected imino, lower alkylamino, protected lower alkylamino, mono(or di)(lower)alkylcarbamoyloxy, lower alkylidene, lower alkanimidoyl and imino-protective group, or pharmaceutically acceptable salts thereof.
Claim 2
Dependent Claim 141 words
A compound of the formula: ##STR71## in which R 1 is carboxy or protected carboxy, R 2 is hydoxy(lower)alkyl or protected hydroxy(lower)alkyl, R 3 and R 4 are each hydrogen or lower alkyl, and R 5 is saturated 4 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) or saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), wherein said aliphatic heterocyclic group may be substituted by one or more suitable substituent(s) selected from a group consisting of hydroxy, protected hydroxy, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, halogen, lower alkoxy, lower alkyl, lower alkoxy(lower)alkyl, imino, protected imino, lower alkylamino, protected lower alkylamino, mono(or di)(lower)alkylcarbamoyloxy, lower alkylidene, lower alkanimidoyl and imino-protective group, or pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim 70 words
A compound of claim 1, wherein R 5 is azetidinyl, N-protected azetidinyl, pyrrolidinyl, N-protected pyrrolidinyl, piperidinyl, N-protectede piperidinyl, morpholinyl or protected morpholinyl, each of which may be substituted by one or two suitable substituent(s) selected from a group consisting of hydroxy, protected hydroxy, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, halogen, lower alkoxy, lower alkyl, lower alkoxy(lower)alkyl, imino, protected imino, lower alkylamino, protected lower alkylamino, mono(or di)(lower)alkylcarbamoyloxy, lower alkylidene, lower alkanimidoyl and imino-protective group.
Claim 4
Dependent Claim 96 words
A compound of claim 2, wherein R 1 is carboxy or esterified carboxy, R 2 is hydroxy(lower)alkyl, acyloxy(lower)alkyl, C 6 -C 10 ar(lower)alkyloxy(lower)alkyl, tri(lower)alkylsilyloxy(lower)alkyl, tri(C 6 -C 10 )arylsilyloxy(lower)alkyl or tris[(C 6 -C 10 )-ar(lower)alkyl]silyloxy(lower)alkyl, and R 5 is azetidinyl, 1-(lower alkenyloxycarbonyl)azetidinyl, pyrrolidinyl, 1-(lower alkenyloxycarbonyl)-pyrrolidinyl, piperidinyl, 1-(lower alkenyloxycarbonyl)piperidinyl, morpholinyl or 4-(lower alkenyloxycarbonyl)morpholinyl, each of which may be substituted by one or two suitable substituent(s) selected from a group consisting of hydroxy, tri(lower)alkylsilyloxy, hydroxy(lower)-alkyl, tri(lower)alkylsilyloxy(lower)alkyl, halogen, lower alkoxy, lower alkyl, lower alkoxy(lower)alkyl, imino, lower alkenyloxycarbonylimino, lower alkylamino, N-(lower alkenyloxycarbonyl)-N-(lower)-alkylamino, mono(or di)(lower)alkylcarbamoyloxy, lower alkylidene, lower alkanimidoyl and acyl.
Claim 5
Dependent Claim 87 words
A compound of claim 3, wherein R 1 is carboxy, lower alkenyloxycarbonyl or phenyl(or nitrophenyl)(lower)alkoxycarbonyl, R 2 is hydroxy(lower)alkyl, lower alkenyloxycarbonyloxy(lower)alkyl, phenyl(or nitrophenyl)(lower)alkoxycarbonyloxy(lower)alkyl or tri(lower)alkylsilyloxy(lower)alkyl, and R 5 is pyrrolidinyl, 1-(lower)alkenyloxycarbonylpyrrolidinyl, 1-(lower)alkanimidoylpyrrolidinyl, hydroxyprrolidinyl, 1-(lower alkenyloxycarbonyl)(hydroxy)pyrrolidinyl, 1-(lower alkenyloxycarbonyl)[tri(lower)alkylsilyloxy]pyrrolidinyl, lower alkoxypyrrolidinyl, 1-(lower alkenyloxycarbonyl)(lower alkoxy)pyrrolidinyl, [di(lower)alkylcarbamoyloxy]pyrrolidinyl, 1-(lower alkenyloxycarbonyl)[di(lower)alkylcarbamoyloxy]pyrrolidinyl, (lower alkylcarbamoyloxy)pyrrolidinyl, 1-(lower alkenyloxycarbonyl)(lower alkylcarbamoyloxy)pyrrolidinyl, (lower alkylamino)pyrrolidinyl, 1-(lower alkenyloxycarbonyl)[N-(lower)alkenyloxycarbonyl-N-(lower)alkylamino]pyrrolidinyl, halopyrrolidinyl, 1-(lower alkenyloxycarbonyl)halopyrrolidinyl, [lower alkoxy(lower)alkyl]pyrrolidinyl, 1-(lower alkenyloxycarbonyl)[lower alkoxy(lower)alkyl]pyrrolidinyl, [hydroxy(lower)alkyl]pyrrolidinyl, 1-(lower alkenyloxycarbonyl)[hydroxy(lower)alkyl]pyrrolidinyl, 1-[lower alkylamino(lower)alkanoyl]pyrrolidinyl, 1-[N-(lower)alkenyloxy-carbonyl-N-(lower) alkylamino(lower)alkanoyl]pyrrolidinyl, (lower alkyl)(imino)pyrrolidinyl,, 1-(lower alkyl)(lower alkenyloxycarbonylimino)pyrrolidinyl, piperidinyl, 1-(lower alkenyloxycarbonyl)piperidinyl, azetidinyl, 1-(lower alkenyloxycarbonyl)azetidinyl, morpholinyl, 4-(lower)alkenyloxycarbonylmorpholinyl, lower alkylidenepyrrolidinyl or 1-(lower)alkenyloxycarbonyl(lower alkylidene)pyrrolidinyl.
Claim 6
Dependent Claim 94 words
A compound of claim 4, wherein R 1 is carboxy, R 2 is hydroxy(C 1 -C 4 )alkyl, R 3 is hydrogen, R 4 is hydrogen or C 1 -C 4 alkyl, and R 5 is pyrrolidinyl, hydroxypyrrolidinyl, C 1 -C 4 alkoxypyrrolidinyl, [di(C 1 -C 4 )alkylcarbamoyloxy]pyrrolidinyl, (C 1 -C 4 alkylcarbamoyloxy)pyrrolidinyl, C 1 -C 4 alkylaminopyrrolidinyl, halopyrrolidinyl, [C 1 -C 4 alkoxy(C 1 -C 4 )alkyl]pyrrolidinyl, [hydroxy(C 1 -C 4 )alkyl]pyrrolidinyl, 1-[C 1 -C 4 alkylamino(C 1 -C 4 )alkanoyl]pyrrolidinyl or 1-[(C 1 -C 4 )alkyl]iminopyrrolidinyl or C 1 -C 4 alkylidenepyrrolidinyl.
Claim 7
Dependent Claim 59 words
A compound of claim 5, which is selected from a group consisting of (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3[(E)-2-{(2S)-pyrrolidin-2-yl}-1-methylethenyl]-1azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[2-{(2S,4R)-4-hydroxypyrrolidin-2-yl}-1-methylethenyl]-7oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-3-[(E)-2-{(2S)-1-acetimidoylpyrrolidin-2-yl}-1-methylethenyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[2-{(2S,4R)-4-methoxypyrrolidin-2-yl}-1-methylethenyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-caroxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[2-{(2S,4R)-4-(methylcarbamoyloxy) pyrrolidin-2-yl}-1-methylethenyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2carboxylic acid, (5R,6S)-3-[2-{(2S,4R)-4-(dimethylcarbamoyloxy)-pyrrolidin-2-yl}-1-methylethenyl]- 6[(1R)-1hydroxyethyl]7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[2-{(2S,4S)-4-(methylamino) pyrrolidin-2-yl}-1-methylethenyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-3-[2-{(2S)-4-fluoropyrrolidin-2-yl}-1methylethenyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[2-(5-methoxymethylpyrrolidin-2-yl-1-methylethenyl]- 7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-3-[2-(5-hydroxymethylpyrrolidin-2-yl)-1methylethyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-1azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[2-(pyrrolidin-3-yl)-1-methylethenyl]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[2-yl}-1-methylethenyl]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[2-{(2S)-1-(N-methyaminoacetyl) pyrrolidin-2-yl}-1-methylethenyl]-7-oxo-1-azabicyclo[ 3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R-1-hydroxyethyl]-3-[2-{(2S)-5-imino-1-methylpyrrolidin-2-yl}-1-methylethenyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(E)-2-{(2S)-pyrrolidin-2-yl}-1-ethenyl]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-3-[(E)-2-{(2S)-1-formimidoylpyrrolidin-2-yl}-1-methylethenyl]- 6-[(1R)-1-hydroxyethyl]-7-oxo-1azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[2-{(2S,4S)-4-hydroxypyrrolidin-2yl}-1-methylethenyl]-7-oxo-1-azabicyclo[[3.2.0]hept-2-ene-2-carboxylic acid, (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[2-{(2S)-4-methylenepyrrolidin-2-yl}1-methylethenyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid and (5R,6S)-6-[(1R)-1-hydroxyethyl]-3-[2-{(2S,4S)-4-methoxypyrrolidin-2-yl}-1-methylethenyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-carboxylic acid.
Claim 8
Dependent Claim 22 words
An antimicrobial composition comprising, an effective amount of a compound of claim 1, in admixture with a pharmaceutically acceptable carrier or excipient.
Claim 9
Dependent Claim 30 words
A method for the treatment of infectious diseases caused by pathogenic bacteria which comprises administering an effective amount of a compound of claim 1 to a human being or animal.

References Cited (Backward Citations)

US4348320A Cited
US4543257A Cited
EP0010316A1 Cited
EP0010317A1 Cited
US4260627A Cited
US4465632A Cited
US4267188A Cited
EP0072710B1 Cited
US4729993A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-05-07 1993-11-06 1994-05-08 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-05-07 1997-11-06 1998-05-08 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-05-07 2001-11-06 2002-05-08 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag